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ABSTRACT 
 
Cerebral vasospasm (CVS) is a well-known cause of morbidity and mortality amongst 
patients who have suffered from subarachnoid haemorrhage (SAH). Its presence is associated 
with reduced cerebral perfusion and potential further development of neurological deficit. The 
aetiology of CVS has been proven to be multifactorial and several risk factors have been 
associated with its development. Since CVS has been linked to signalling changes in vascular 
endothelium, serum glucose was chosen as a potential prognostic indicator and risk factor due 
to its relation with endothelial dysfunction.  
 
The objective of this study was to evaluate the association between serum glucose 
levels in ICU patients admitted with SAH and the development of CVS. The study is a 
retrospective observational study in which data was collected on patients admitted to the ICU 
of Pauls Stradiņš Clinical University Hospital with the primary diagnosis of SAH. We 
compared serum glucose levels on ICU admission and average glucose levels for the first 5 
days in the ICU in patients with and without subsequent development of CVS. 
 
Twenty-four patients diagnosed with SAH were included in the study. CVS was 
confirmed in 25% (n=6). There was no significant difference in age and gender distribution 
between groups. Patients with subsequent development of CVS had higher WFNS score 
values (4.80 and 3.56; p=0.008). We found lower mean glucose levels on admission for 
patients that developed CVS compared to those that did not develop CVS (7.32 and 9.28 
mmol/L; p=0.05). The average glucose levels on first 24h of ICU stay were also lower in 
patients who developed CVS (7.26 and 9.29 mmol/L; p=0.03). There were no significant 
differences in average glucose levels between groups from day 2 to day 5 of ICU stay. 
Overall mortality was not affected by ICU glucose levels and average glucose levels of first 
24h were negatively correlated to the duration of ICU stay (rs = -0.408, p<0.05). 
 
The study shows that admission and initial average 24h glucose levels may prove to be 
a prognostic indicator for the potential development of CVS after SAH. Glucose averages of 
the first day of ICU stay were significantly related to the development of CVS and may 
demonstrate importance after further investigation, possibly with a larger patient group.  
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I. Abbreviations 
AA – Arachidonic acid  
COX – Cyclooxygenase 
CSF – Cerebrospinal fluid 
CT – Computed tomography 
CTA – Computed tomography angiography 
CTP – Computed tomography perfusion 
CVS – Cerebral vasospasm 
DCI – Delayed cerebral ischemia 
DIND – Delayed ischaemic neurologic deficit 
DSA – Digital subtraction angiography 
EVD – External ventricular drain 
GCS – Glasgow coma scale 
IIT – Intensive insulin therapy 
ICP – Intracranial pressure 
ICU – Intensive care unit 
LOS – Length of stay (total duration of hospital stay) 
LOS-ICU – Length of ICU stay (total duration of ICU stay) 
MRA – Magnetic resonance angiography 
MTT – Mean transit time 
NIHSS – National institutes of health stroke scale 
NO – Nitric oxide 
OxyHb – Oxyhaemoglobin 
PDGF – Platelet derived growth factor 
p.o. – Per os  
PWI – Perfusion weighted imaging 
ROS – Reactive oxygen species  
SAH – Subarachnoid haemorrhage 
SCV – Symptomatic cerebral vasospasm 
TCD – Transcranial doppler 
TCCS – Transcranial color coded sonography 
TGC – Tight glycaemic control 
VSM – Vascular smooth muscle 
WFNSS – World federation of neurological surgeons scale 
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1. INTRODUCTION 
Despite recent advances in surgery and neurocritical care, the mortality of subarachoid 
haemorrhage (SAH) remains at about 50% with 25% of deaths occurring during the first 24 
hours after the event [1]. Although a large amount of deaths are attributed to neurological 
damage resulting from a remarkable build up of intracranial pressure (ICP) after for example 
aneurysmal rupture, the majority of morbidity and mortality is still associated with 
progressive cerebral infarctions that occur as a result of cerebral vasospasm (CVS). 
Approximately 70% of patients who experience aneurysmal SAH will demonstrate 
angiographic evidence of arterial narrowing [2] and about 46% will develop CVS with peak 
onset between days four and fourteen after SAH [1]. Several observational studies have 
demonstrated a variety of factors that may play a role in the potential development of CVS 
after SAH [3-6] however, most of these factors are not clinically modifiable once 
haemorrhage has occurred.  
 
 Diagnosis of this reversible vasculopathy is made by a combination of clinical, 
angiographic and transcranial Doppler ultrasonographic methods [21]. Thus far, the calcium 
channel blocker nimlodipine is the only available pharmacological therapy, which has shown 
to grant some prophylactic benefit in terms of neurological outcome [22]. In patients with 
CVS, hemodynamic therapy (known as “triple H therapy”: haemodilution, hypertension, 
hypervolemia) is usually initiated and refractory vasospasm can be treated with endovascular 
balloon angioplasty in some cases [21]. 
 
Since the pathophysiology of CVS has been linked to signalling changes in vascular 
endothelium [10], serum glucose was chosen as a potential prognostic indicator and risk 
factor due its relation with endothelial dysfunction. Serum glucose has shown to be a relevant 
predictor of outcome after acute brain injury and tight glycaemic control (TGC) in the ICU 
has become standard practice in order to reduce the complications associated with it [7]. In 
SAH, hyperglycaemia on admission has been shown to be a good indicator of severity of the 
ictus and has correlated with functional outcome of the patient [11].  
 
Although a relationship between elevated serum glucose levels and the development 
of CVS has already been established [8, 9, 13], there is limited information about the 
importance of glucose values on ICU admission and initial 24-hour glucose levels in patients 
with SAH and the influence that these parameters have on patient outcome as well as 
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morbidity and mortality.  Given its predictable onset between day four and fourteen after 
bleeding, CVS is a potentially modifiable complication.  
 
The purpose of this study was to examine how admission and dynamic serum glucose 
levels during hospitalization are related to the development of CVS and clinical outcomes 
after SAH. The objective was to evaluate the prognostic significance of serum glucose levels 
in the ICU and the subsequent development of CVS.   
 
2. THEORETICAL BACKGROUND 
2.1. Vasospasm in General 
 
The earliest description of a patient with delayed cerebral ischemia was perhaps by Sir 
William Gull in 1859 [51]. In his research entitled “cases of aneurysm of the cerebral vessels” 
he described the case of a 30-year-old female who whilst walking suddenly called out, “Oh 
my head,” vomited and fainted shortly afterwards. She was admitted to the hospital at noon 
the following day. Upon examination, her right arm and leg were fairly paralyzed, the 
muscles flaccid. Her condition improved, and she was able to eat 3 days after the ictus. On the 
4th day, she spoke some words, but on the 5th day, her condition worsened. Her pupils 
became fixed, dilated, and she died. The subsequent autopsy showed SAH in the left Sylvian 
fissure with massive softening of the left cerebral hemisphere and two aneurysms of the 
middle cerebral artery, one of which had ruptured.  
 
In 1949, Australian Physiologist Graeme Robertson described the post mortem 
findings of 27 Patients who suffered from aneurysm rupture and subsequent SAH. He found 
infarctions in brain parenchyma supplied by patent arteries and concluded: “Hence, it seems 
possible that the ischaemic changes were due to temporary spasm of the supplying vessels.” 
[52].  As medical technology progressed, Robertson’s hypothesis was proven correct in 1951 
when Ecker and Reichmeider at Syracuse Memorial Hospital, New York were able to 
visualise alterations in the diameter of cerebral arteries by comparing angiograms taken on 
consecutive days in 350 different patients [71]. A marked reduction in vessel calibre was 
noted in 11 of the cases with aneurysmal SAH, which returned to normal over the course of 
several days.  These findings firmly established the concept of CVS in the field of neurology.  
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In 1964, Stonelli and French found vasospasms confirmed by angiogram less 
frequently in patients who went on to make a good postoperative recovery [72]. The findings 
led to improvement in the management of patients with SAH. Increasing blood pressure to 
150-170/90-100 mmHg using vasopressors was found to reduce neurological deficits. This 
marked the beginning of the modern triple H therapy (haemodilution, hypertension and 
hypervolaemia) together with the findings of Kosnick and Hunt in 1976 [73]. The researchers 
demonstrated improvement of neurological deficits in six out of seven patients with 
aneurysmal SAH using norepinephrine, hypertonic saline and albumin.  
 
 Fischer was the first to describe the clinical characteristics of delayed cerebral 
ischemia (DCI) in 1975 as an onset about 3-13 days after a single SAH, in about one third of 
patients. These criteria have remained true until present day. The general time course of 
angiographic vasospasm was further evaluated by Weir et. al. by measuring the diameters of 
cerebral arteries on 627 angiograms from 293 patients with ruptured aneurysms [52]. The 
research showed that angiographic CVS usually portrayed an onset at 3 days, was maximal at 
6-8 days and resolved by 12 days. The invention of computed tomography (CT) eventually 
aided in predicting the onset, location and potential severity of CVS, leading to Fischer et. al. 
classifying CT-hyperdense subarachnoid blood into four grades, which could be used to 
predict whether angiographic vasospasm would occur and how severe it would be [53].  
 
2.2. Pathophysiology of Cerebral Vasospasm 
 
The pathophysiology behind delayed vasospasm after SAH has been the subject of 
multiple studies, continuing controversies and on-going search for the substance or substances 
that may cause this clinically frustrating complication. Effective therapeutic development has 
been largely hindered by the fact that the underlying pathogenic mechanisms still remain 
poorly understood. Nevertheless, intensive research over the past three decades has identified 
certain mechanisms that may play a role in its development. 
 
Experimental data suggests that the causative agents of CVS can generally be divided 
into two main categories: (1) compounds found in blood or metabolites of compounds found 
in blood and (2) compounds that are regulated or induced as a consequence of blood around 
the vessels. Reactions involving free radicals, an imbalance between vasoconstrictor and 
vasodilator substances, inflammatory processes, neurogenic factors that regulate vascular 
tone, membrane pathology and endothelial apoptosis have all been postulated as causative 
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agents. Since CVS tends to occur more frequently and intensively in vessels surrounding large 
blood clots [23], the rationale that blood itself or metabolites of components of blood cause 
vasospasm remains compelling. 
 
2.2.1. Smooth Muscle Contraction and Spasmogens 
 
The essence of CVS can be defined as a prolonged and abnormal contraction of 
vascular smooth muscle cells (VSM). It is well known that VSM contraction and relaxation is 
fundamentally maintained by the presence of free intracellular calcium either through calcium 
channels or by release of calcium from internal stores (e.g. sarcoplasmic reticulum). Blood 
products and/or metabolites released after SAH are believed to stimulate cell membrane 
receptors, such as G-protein-coupled receptors and receptor tyrosine kinases, which may 
stimulate calcium influx from the extracellular space or release of calcium from the 
intracellular pool ultimately leading smooth muscle cell contraction (Fig. 2.2.1) [24].  
 
Figure 2.2.1 Mechanisms involved in vascular smooth muscle contraction. (Source: 
Klabunde, R.E. Cardiovascular Physiology Concepts. Lippincott Williams & Wilkins, 
2011) 
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Experimental studies have shown that breakdown products of blood in the subarachnoid 
space are involved, directly or indirectly, in the development of CVS after SAH. The most 
prominent spasmogenic agent responsible for the development of CVS is believed to be 
oxyhaemoglobin (OxyHb) [25, 26, 27] with its ability to: 
 
• Induce direct vasoconstriction 
• Release arachidonic acid (AA) metabolites and endothelin from the arterial wall 
• Inhibit vasodilation through nitric oxide (NO) scavenging  
• Damage perivascular nerves 
• Promote free radical reactions through generation of reactive oxygen species (ROS)  
 
Furthermore, OxyHb is present in high concentrations in the cerebrospinal fluid (CSF) 
during the time of CVS and changes in OxyHb concentrations tend to mirror the evolution of 
CVS [26].  
 
2.2.2. Free Radicals 
 
 A free radical is an uncharged molecule (typically highly reactive and short-lived) 
having an unpaired valency electron [28]. The term reactive oxygen species (ROS) is used to 
describe radicals such as superoxide (O2-) and hydroxyl (OH) and non-radical derivatives of 
oxygen such as hydrogen peroxide (H2O2) [29].  
 
The formation of ROS after SAH is thought to be due to the autoxidation of OxyHb 
into methemoglobin. This leads to the production of O2-, which is converted to H2O2 by 
superoxide dismutase. H2O2 can then be converted to OH through the Fenton reaction or 
together with O2- may undergo the iron-catalyzed Haber-Weiss reaction, also generating OH. 
OH can combine with lipids to form lipid peroxides which themselves are capable of spasm 
and damaging the structure of arteries as well as directly or indirectly activating the protein 
kinase C pathway leading to CVS [30]. O2- itself could also contribute to CVS by 
inactivating the powerful vasodilator nitric oxide, however, the principal free radical source in 
vasospasm remains OH with its ability to produce lipid peroxides (Fig. 2.2.2). 
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Figure 2.2.2 Free radicals after SAH. (Source: Kolias, A.G. et.  al.  
Pathogenesis of Cerebral Vasospasm Following Aneurysmal Subarachnoid 
Hemorrhage: Putative Mechanisms and Novel Approaches. Journal of 
Neuroscience Research, 2009)  
 
 
Polidori et. al. has shown that patients with CVS displayed elevated levels of lipid 
peroxides in their CSF [31] and the fact that antioxidant agents such as 1,2-bis(nicotinamide)-
propane, tirilazad, and ebselen have improved experimental vasospasm and reduced lipid 
peroxidation in animal models provides evidence in support of the role of free radicals in the 
pathogenesis of CVS [32]. 
 
2.2.3. Endothelial Factors – Nitric Oxide and Endothelins 
  
It is well known that endothelial factors such as nitric oxide  (NO) and endothelins 
play a large role in maintaining vascular smooth muscle tone with the former generally 
responsible for smooth muscle relaxation and the latter responsible for smooth muscle 
contraction. In physiological states, a delicate balance exists between endothelium-derived 
vasoconstrictor and vasodilator substances. NO released from l-arginine in vivo activates 
soluble guanylyl cyclase, which catalyzes the conversion of guanosine triphosphate to cGMP 
ultimately leading to smooth muscle relaxation [33]. The role of NO in the development of 
CVS can be attributed to several influencing factors:  
 
• OxyHb scavenges readily available NO [34]. 
• Neuronal death due to ischemia leads to a decrease in neuronal nitric oxide synthase 
(nNOS) and subsequently decreased NO production [34]. 
• Asymmetric dimethylarginine (ADMA), which is synthesized during the methylation 
of l-arginine residues, inhibits endothelial nitric oxide synthase (eNOS) [35]. 
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• Increases in inducible nitric oxide synthase (iNOS) leads to the generation of free 
radicals such as OH [36]. 
 
Evidence in support of the role of NO in the pathogenesis of CVS is provided by the fact 
that a variety of NO donors, delivered in different ways, have been shown to reverse or 
prevent vasospasm in animal models [37] and Simvastatin, which is capable of increasing 
eNOS activity has ameliorated vasospasm in mice [38]. 
 
 Among the four different isoforms of ET in humans, ET-1 plays the largest role in 
vasoconstriction after SAH [39]. It is primarily produced by the endothelium itself, but can 
also originate from astrocytes and neurons [39]. Apart from causing vasoconstriction, ET 
possesses the ability to remodel and induce structural and inflammatory changes within the 
blood vessels themselves. Studies have shown that cerebral blood vessels may be sensitized to 
ET-1 after SAH and that an up-regulation of ETA receptors occurs following the ictus [40]. 
The ET-1–ET receptor interaction results in the activation of phospholipase C, which 
ultimately leads to an increase in intracellular calcium and activation of phosphokinase C 
[40].  
 
2.2.4. Arachidonic Acid and its Metabolites 
 
Arachidonic acid, as a structural component of cell membrane phospholipids, can be 
metabolised into a wide variety of biologically active substances by enzymes such as 
cyclooxygenase (COX). The COX pathway ultimately results in the formation of Prostacyclin 
(PGI2) (powerful vasodilator), Thromboxane (TXA2), and Prostaglandins such as PGE2 and 
PGF2a, which are capable of vasoconstriction [50]. In 1979, Boullin et. al described an 
imbalance between vasoconstricting PGs, TXA2 and the vasodilating PGI2 as a possible 
mechanism for CVS.   
 
2.2.5. Neurogenic Factors 
  
Cerebral arteries have sensory, sympathetic and parasympathetic innervation. Direct 
vascular contact with surrounding subarachnoid blood is postulated to cause an impairment in 
vascular innervation, a phenomenon described as denervation by Sercombe et. al. in 2002 
[41]. Unfortunately not much information has been attained in this area and in fact studies 
have shown that sympathetic denervation appears to ameliorate CVS in experimental models 
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[42]. Studies have also shown that lesions in pathways of brainstem reflexes responsible for 
controlling cerebrovascular tone have prevented the establishment of vasospasm in 
experimental models [43]. This may prove the hypothesis that SAH activates local reflexes 
that act over brainstem nuclei to constrict cerebral arteries. Despite scientific evidence, it is 
still widely believed that neurogenic factors perhaps only play an ancillary and not central 
role in the pathogenesis of CVS [44]. 
 
2.2.6. Structural Factors 
 
 The structural factors relating to the development of CVS are mainly based on the fact 
that experimental studies have demonstrated that the presence of blood in the subarachnoid 
space leads to increased proliferative activity across all layers of the arterial wall, mainly 
involving the adventitia and endothelium [45]. The hypothesis remains that substances such 
as platelet-derived growth factor (PDGF) released from aggregated platelets at the 
subarachnoid clot may contribute to CVS by thickening the arterial wall [46]. Endothelial 
apoptosis, leading to impairment of endothelium-dependent vasorelaxation and increased 
exposure to spasmogens, has also been observed after CVS [47] and recently p53, a 
transcription factor that acts as a tumour suppressor, has been implicated in both apoptosis 
and cellular proliferation in relation to CVS [48, 49]. Although the evidence of cell 
proliferation and consequent arterial wall thickening after SAH is existent, the role of this 
phenomenon in the pathogenesis of CVS remains controversial as proliferation is limited and 
there appears to be no significant wall thickening during the period of maximal intensity of 
the vasospasm [42].   
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2.3. Diagnostic Principles of Cerebral Vasospasm 
 
 The initial suspicion of CVS is generally raised after sudden onset of new focal / 
cognitive neurologic deterioration roughly four to fourteen days after SAH, more widely 
known as delayed ischaemic neurologic deficit (DIND) which may encompass typical stroke 
symptoms such as newly acquired muscle weakness, aphasia or confusion manifested as a 
sudden drop in Glasgow Coma Scale (GCS) rating / rise in National Institutes of Health 
Stroke Scale (NIHSS). The fact that many SAH patients will initially be treated in an ICU 
setting and often kept sedated makes an accurate neurologic status evaluation difficult.  
 
The current gold standard for effectively diagnosing CVS remains cerebral 
angiography (DSA) with accurate depiction of the vessels of the brain by intra-arterial 
contrast agent application and subsequent digital subtraction x-ray imaging. This procedure is 
invasive, requires the availability of significant resources and may lead to complications in up 
to 2.63% of cases ranging from benign conditions such as access-site haematoma (4.2%) to 
stroke with permanent disability (0.14%) or even death (0.06%) [55].  
 
Figure 2.3.1 Vertebrobasilar angiograms obtained from a patient with SAH after right 
AICA aneurysm rupture (A). Image (B) represents a 50% right P2 PCA segment 
stenosis 12 days after coil-embolization of the aneurysm. The arrowheads in (C) indicate 
improved angiographic vasospasm in the left distal vertebral artery, superior cerebellar 
arteries and posterior circulation following treatment with 10-mg intra-arterial 
Verapamil. (Source:  Sehy, J.V., et.al. Improvement in Angiographic Cerebral Vasospasm 
after Intra-Arterial Verapamil Administration. AJNR, 2010.) 
 
 
 
CT-Angiography (CTA) is a less invasive alternative that in conjunction with CT-
Perfsuion (CTP) has gained popularity for diagnosing CVS and evaluating whether 
endovascular therapy will be required. It too uses x-ray imaging technology and derives 
images of vessels in 3 dimensions with the ability to quantitatively depict cerebral blood flow 
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and cerebral blood volumes by means of CTP.  In a study performed by Wintermark et. al. in 
2006, CTA and CTP represented an accurate screening test in patients with suspected CVS. 
Post-contrast vessel narrowing and a CTP-derived mean transit time (MTT) with a threshold 
of 6.4 seconds represented the most accurate combination for the definite diagnosis of CVS 
[56]. MR-Angiography (MRA) with perfusion-weighted imaging (PWI) is another alternative 
that eliminates the CT drawbacks of radiation exposure, however adds the disadvantage of 
extended examination times and inferior vessel resolution compared to both DSA and CTA.  
 
Figure 2.3.2. DSA (A), CTA (B, C) and CTP (D, E, F) images of a 44-year-old patient 6 
days after rupture and clipping of a left MCA bifurcation aneurysm.  DSA showed 
moderate vasospasm of the distal left ICA and severe vasospasm of the left ACA A1 
segment and left MCA M1 / proximal M2 segments (arrowheads, A). Correlating CTA 
image with increased MTT / CBV (D / F) and normal CBF (E) in the respective left 
MCA territory. Image (C) represents resolution of the vasospasm following intra-
arterial Nimlodipine therapy.  (Source: Binaghi, S., et. al. CT Angiography and Perfusion 
CT in Cerebral Vasospasm after Subarachnoid Hemorrhage. AJNR, 2007.) 
 
 
 
Transcranial Doppler ultrasonography or contrast-enhanced / non-contrast-enhanced 
transcranial color-coded sonography is another potentially non-invasive method, primarily 
used to measure blood flow in large proximal intracranial vessels. The flexible nature of 
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ultrasonography allows this procedure to be performed at the patient’s bedside without the 
hazards of radiation exposure. Unfortunately these modalities are heavily operator dependent 
and provide limited feedback in patients with hyperostosis of the temporal bones. In 2004 the 
American Academy of Neurology recognized TCCS as an effective method in diagnosing 
CVS but recommended its use only for the middle cerebral artery (MCA) where the 
diagnostic applicability was seen in 67% of patients with a sensitivity of 100% and specificity 
of 93%. These percentages decreased with regard to other vessels in the brain, especially 
those of the posterior circulation [57].  
 
2.4. Treatment Principles of Cerebral Vasospasm 
 
 Although therapeutic approaches and the availability of therapeutic resources vary 
from clinic to clinic, the evidence based principles in the treatment of CVS after SAH remain 
similar around the globe. The therapeutic approach of CVS already commences once SAH is 
diagnosed and is usually based on three vital components: (1) prompt reduction of ICP, (2) 
optimization of the rate of cerebral oxygen demand and (3) improving cerebral blood flow. A 
prompt ICP reduction may be achieved by surgical means of early ventriculostomy and 
external ventricular drainage (EVD) in conjunction with endovascular / open surgical 
treatment of the bleeding source if visible on routine imaging. Early ICP reduction and 
bleeding source treatment allows for more aggressive further potential CVS treatment over 
the course of care.  
 
The improvement of cerebral blood flow remains the most important aspect of CVS 
therapy. Alongside calcium channel blockers, triple H therapy has gained widespread 
acceptance over the past 20 years and encompasses three main physiologic components, 
namely: hypertension, haemodilution and hypervolemia. The rationale behind this treatment is 
that maintenance of high circulating blood volume, increased perfusion pressures, and 
decreased blood viscosity will enhance CBF in the setting of vasoconstriction [69]. Volume 
expanding fluids increase cardiac output which in turn increases blood pressure resulting in 
increased CBF in hypo perfused cerebral territories. Hypertension may be achieved by 
volume expanding fluid therapy alone but can also be realized by vasoactive drugs such as 
dopamine or phenylephrine. Haemodilution with a target haematocrit of 30-35% is 
implemented as a reasonable balance between reduced blood viscosity and oxygen-carrying 
capacity.  
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Despite being in use for well over 30 years, the therapeutic approach with Triple-H 
has undergone scrutiny within the past decade to determine whether each of the three 
individual therapeutic components share similar therapeutic value. Hypervolaemia and 
haemodilution remain the most controversial components of haemodynamic therapy to this 
day. A randomized controlled trial with 82 patients performed in 2000 by Lennihan et. al. 
showed that hypervolaemic therapy did not increase CBF or blood volume compared with 
normovolaemic therapy [58]. Another study performed in 2001 showed neither early nor late 
outcome measure differences (in particular no differences in CBF) between patients treated 
with Hypervolaemic fluid therapy and those treated with normovolaemia [59]. With regards 
to haemodilution, issues are seen as to whether an increased CBF due to reduced blood 
viscosity can outweigh the expense of severe decreases in oxygen delivering capacities [60].  
In 2010, Dankbaar et. al. performed a widespread literature review to evaluate the effects of 
the individual triple H components on the cerebral blood flow (CBF) of patients following 
CVS. Although none of the 11 studies included in the review contained a control group, it 
became evident that hypertension appears to be more effective in increasing CBF than 
haemodilution or hypervolaemia [54]. 
 
Figure 2.4.1. Balloon angioplasty of the left MCA M1 segment due to vasospasm 
following left PCOM aneurysm rupture. Depicted: proximal and distal ends of the 
balloon (white arrows) and inflated balloon (black arrows). (Source: Prof. Alan 
Coulthard. From the case: Balloon angioplasty for cerebral vasospasm. Radiopedia.org, 
2016.) 
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 Although there is still much controversy today as to which techniques are best, which 
patients are the best candidates and which is the best time to intervene, more invasive 
techniques such as endovascular balloon angioplasty and intra-arterial administration of 
vasodilators have proven to be effective methods in increasing CBF and improving patient 
outcome [70]. If little angiographic spasm presents in the proximal intracranial vessels, then 
intra-arterial administration of vasodilators such as Nimlodipine may suffice. In the larger 
cerebral vessels, balloon angioplasty has shown to be very effective, even as a prophylactic 
measure for CVS as Zwienenberg-Lee et. al. described in 2008 [61]. The overall competence 
in regards to radiographic resolution of CVS is similar between both methods and one study 
comparing their effectiveness showed no difference in clinical patient outcomes [62]. 
 
2.5. Current State of Research  
 
2.5.1. Factors Associated with the Development of Cerebral Vasospasm 
 
The current state of research regarding patient-specific or clinical factors which may 
increase / reduce the likelihood of developing SCV after SAH is broad. The statistical 
significance of independent risk factors often varies between individual studies and 
contradicts each other respectively. In order to gain a complete understanding of potential risk 
factors, Inagawa, T. performed an extensive literature review in 2016 including Twenty-one 
clinical studies in which 23 multivariate analyses were performed on factors predictive of 
CVS after SAH. He concluded that severe SAH evident on CT-imaging appeared to be the 
only definite consistent risk factor for CVS after SAH, followed by cigarette smoking, 
hypertension, and left ventricular hypertrophy on electrocardiogram [63].  The effects of 
various other risk factors such as age, clinical grade, hydrocephalus, etc. appeared to be 
related to the severity of SAH rather than being independent risk factors for the development 
CSV [63]. 
2.5.2. Serum Glucose and the Development of Cerebral Vasospasm 
 
 
With regards to serum glucose, there is as well a large discrepancy between individual  
studies in its potential contribution to the development of CVS. Several studies have 
suggested that hyperglycaemia is associated with an increased incidence of CVS [9, 13]. 
Other studies found no relationship between hyperglycaemia and SCV [4, 64] whereas a 
single study performed by Naidech et. al. showed that moderate hypoglycaemia was 
associated with CVS and worse functional outcome in multivariate models with focus being 
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placed on the nadir blood glucose values throughout hospital stay [14]. The above-mentioned 
studies will further be examined and contrasted in the discussion and conclusion parts of this 
dissertation.   
3. MATERIALS AND METHODS 
3.1. Hypothesis and Aim 
 
 Over the course of the past decade, several studies have been performed to assess 
potential risk factors in the development of CVS (see 3.5). A great majority of these risk 
factors are patient specific and represent conditions / characteristics, often chronic, which may 
not be altered in an ICU setting. Other factors represent dynamic features that can be 
controlled and adapted artificially with little delay. Serum glucose represents an entity that 
can easily be obtained from a patient’s blood sample, analysed and artificially raised / 
lowered. With this in mind, the objective of this study was to further evaluate the association 
between serum glucose levels in ICU patients admitted with SAH and the development of 
CVS with emphasis being placed on the dynamic inpatient blood glucose levels. The aim was 
to gain a better understanding about the role of glycaemic control in ICU patients diagnosed 
with SAH. 
 
3.2. Study Design 
 
The study is a retrospective observational study in which data was collected on all 
patients admitted to the ICU of Pauls Stradiņš Clinical University Hospital with the primary 
diagnosis of SAH (International Classification of Diseases, tenth revision, diagnostic codes 
I60 and S06.6). The study included patient data gathered from January 2015 to January 2016 
with a proven diagnosis of either traumatic or aneurysmal SAH after detailed case history 
review. Patients were included regardless of age or gender. Only patients admitted within 48 
hours of ictus and surviving the first seven days of hospitalisation were considered. The 
remaining patients were excluded from the study. The study gained institutional approval by 
the ethical committee of Rīgas Stradiņa universitāte on 29.10.2015 (Nr. 0003), signed by the 
committee chairman Prof. Olafs Brūvers. 
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3.3. Patient Variables 
 
3.3.1 Clinical and Baseline Characteristics 
 
Various patient-specific information was extracted from the data at hand in order to 
gain an overview about potential factors in conjunction with blood glucose itself that could 
contribute towards the development of CVS.  Clinical and baseline characteristics including 
age, sex, Fischer grade, World Federation of Neurological Surgeons Scale (WFNSS) and 
medical history of chronic hypertension, diabetes and cardiovascular disease were extracted. 
SAH related conditions such as the presence of cerebral oedema on initial radiographic 
examination, AVM and hydrocephalus were also recorded.  
 
3.3.2. Glycaemic Characteristics 
 
The admission blood glucose (first blood glucose value [mmol/L] documented in the 
patient’s ICU medical record), daily blood glucose and discharge blood glucose (last blood 
glucose value [mmol/L] documented in the patient’s ICU medical record) were recorded. All 
patients had multiple blood glucose measurements taken each day throughout their ICU stay 
and insulin use as well as glucose administration were recorded. The average of all blood 
glucose values from one day was considered the mean daily blood glucose value. The mean 
daily blood glucose values for the first fourteen days after SAH as well as for the entire ICU 
stay were averaged to represent a mean inpatient blood glucose value. Additionally, a median 
blood glucose value for the first fourteen days after SAH as well as for the entire ICU stay 
was noted. The most frequent blood glucose value was considered the mode blood glucose 
value. The highest blood glucose value recorded was considered the maximum blood glucose 
value and the lowest blood glucose value recorded was considered the minimum blood 
glucose value. The glycaemic range was measured as the difference between the maximum 
blood glucose value and the minimum blood glucose value of the first fourteen days after 
SAH as well as for the entire ICU stay.  
 
3.3.3. Hyperglycaemia Cut-off Value 
 
Hyperglycaemia was defined as an admission blood glucose value, mean 24-hour 
blood glucose value and mean inpatient blood glucose value of ≥ 7.8 mmol/L. This cut-off 
value was based on the American Association of Clinical Endocrinologists and American 
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Diabetes Association guidelines that suggest a glycaemic target of 140 – 180 mg/dL (7.8 – 10 
mmol/L) [21]. 
 
3.4. Outcome Measures 
 
3.4.1 Diagnostic Criteria of CVS 
 
The presence of vasospasm was established via the results of CT-Angiography (CTA). 
The decision for performing CTA was based upon worsening of neurologic symptoms such as 
a drop in GCS / rise in NIHSS or new onset of focal neurologic deficits which were identified 
by an ICU nurse during routine neurologic status evaluation and confirmed by a medical 
doctor. Diagnostic criteria involved a comparison of the lumen of the suspected vessel (s) 
with a normal segment of artery both proximal and distal to the narrowing as well as 
comparison to CTA images before the onset of the newly discovered neurologic deterioration. 
Bedside ultrasonography was not regularly performed in the ICU setting and digital 
subtraction angiography (DSA) was only performed if CVS could not be ruled out or if 
endovascular balloon angioplasty / intra-arterial administration of vasodilators was planned.  
 
3.4.2. ICU Treatment regimen for CVS 
 
As standard practice, all patients diagnosed with SAH in the ICU received 
nimlodipine prophylactically (intravenous 5 ml/h for two days, then converted to p.o. 60 mg 
every 4 hours for 14-21 days after SAH). Intensive care management for patients that either 
displayed an onset of clinical symptoms / neurologic deterioration or CTA evidence of 
vasospasm included triple-H therapy (hypertension, haemodilution and hypervolemia).  
 
In the ICU of Pauls Stradiņš Clinical University Hospital, patients are generally 
maintained with sedation following SAH, especially if they are artificially ventilated. When 
sedation is necessary, midazolam ± fentanyl is used. Per protocol, the sedative dose was 
reduced every day to allow the nursing staff to conduct accurate neurologic assessments of the 
patient. Clinical outcome measures were comprised of the total duration of hospital stay 
(LOS), the total duration of ICU stay (LOS-ICU) and mortality.  
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3.5 Statistical Analysis 
 
All data was gathered using Microsoft Excel for Mac (2011, v.14.5.7:151005) and 
analysed using IBM SPSS Statistics (2015, v.23.0.0.0). Statistical analysis succeeded 
independently after consultation with the statistics department of Riga Stradiņš University, 
Faculty of Medicine. Nominal data was reported as true / false or present / absent and 
analysed with a chi-square test where appropriate. Continuous (scale) and ordinal data were 
reported as mean ± SD and their differences were analysed using independent samples t-test 
after the data showed normal distribution using the Kolmogorov-Smirnov test (Figures 3.5.1 
and 3.5.2). Correlation between continuous (scale) data was also analysed using Spearman 
correlation. Descriptive statistics were implemented for baseline and clinical characteristics of 
the patient groups. 
 
 Blood glucose values for each patient group (presence of CVS or no presence of CVS) 
were reported as mean ± SD and median values. The analysis of the two groups involved 
interpretation of the means and application of independent samples t-test. Independent 
samples t-test was also applied for blood glucose values using mortality as a grouping 
variable and clinical characteristics such as cerebral oedema, hydrocephalus, hypertension, 
cardiovascular disease and diabetic status were analysed using chi-square test.  
 
Hyperglycaemia on admission, hyperglycaemia after 24 hours and hyperglycaemia 
after 14 days were treated as nominal data with a cut-off value of 7.8 mmol/L [21] and 
analysed using a chi-square test. A Spearman’s rank correlation coefficient (r) was utilised to 
analyse the relationship between blood glucose values and clinical outcome measures such as 
length of hospital stay (LOS), length of ICU stay (LOS-ICU) and LOS until exitus. 
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Figures 3.5.1. and 3.5.2. Normal distribution of Admission ICU blood glucose values and 
mean inpatient blood glucose values demonstrated by Normal Q-Q Plots.  
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4. RESULTS 
 
4.1. Descriptive Statistics 
 
A total of twenty-four patients diagnosed with SAH were included in the study. Their 
baseline and clinical characteristics are shown in Table 4.1.1. A comparison between patients 
who developed CVS and those who did not develop CVS is shown in Table 4.1.2. 
Table 4.1.1 Baseline and clinical characteristics of twenty-four patients with SAH 
Characteristic No. (%) of Patients 
Age (years) a 56.88 ± 15.46  
Female 12 (50) 
CVS 6 (25) 
WFNSS (points) a 4.00 ± 1.04 
Fischer scale (points) a 4.00 ± 0.00 
Medical history  
 Diabetes mellitus 3 (12.5) 
 Hypertension 13 (54.2) 
 Cardiovascular disease 5 (20.8) 
SAH-related conditions  
 Aneurysm rupture 20 (83.3) 
 Cerebral oedema 9 (37.5) 
 Hydrocephalus 8 (33.3) 
Blood glucose values (mmol/L) a  
 Admission 8.79 ± 2.76 
 24-hour 8.78 ± 2.81 
 Inpatient 8.83 ± 2.38 
Hyperglycaemia b  
 Admission 14 (58.3) 
 24-hour 11 (45.8) 
 Inpatient 13 (54.2) 
Duration of stay (days) a  
 ICU 12.08 ± 7.02 
 Total 19.21 ± 13.08 
Mortality 12 (50) 
a Values presented as mean ± SD, b Blood glucose values ≥ 7.8 mmol/L. 
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Table 4.1.2. Comparison of baseline and clinical characteristics in patients with and 
without CVS 
 CVS: No. (%)  
Variable No (n = 18) e Yes (n = 6) p Value f 
Age (years) a 57.94 ± 15.65 53.67 ± 15.83  NS  
Female 11 (61.1) 1 (16.7) NS 
Male 7 (38.9) 5 (83.3) NS 
WFNSS (points) a 3.56 ± 1.01 4.8 ± 0.45 < 0.05 
Fischer scale (points) a 4.00 ± 0.00 4.00 ± 0.00 NS 
Medical history    
 Diabetes mellitus 1 (5.6) 2 (33.3) NS 
 Hypertension 9 (50) 4 (66.7) NS 
 Cardiovascular disease 4 (22.2) 1 (16.7) NS 
SAH-related conditions    
 Aneurysm rupture 14 (77.8) 6 (100) NS 
 Cerebral oedema 4 (22.2) 5 (83.3) <0.05 
 Hydrocephalus 4 (22.2) 4 (66.7) NS 
Blood glucose (mmol/L) a    
 Admission 9.28 ± 2.93 7.32 ± 1.58 < 0.05 
 24-hour c 9.29 ± 3.04 7.26 ± 1.17 < 0.05 
 Inpatient d 8.95 ± 2.54 8.44 ± 1.98 NS 
Hyperglycaemia b    
 Admission 12 (66.7)  2 (33.3) NS 
 24-hour 10 (55.6) 1 (16.7) NS 
 Inpatient 10 (55.6) 3 (50) NS 
Duration of stay (days) a    
 ICU 12.11 ± 7.90 12.00 ± 3.69 NS 
 Total 21.33 ± 14.49 12.83 ± 2.86 < 0.05 
Mortality 7 (38.9) 5 (83.3) NS 
a Values presented as mean ± SD, b Blood glucose values ≥ 7.8mmol/L, c Average of mean 
glucose values of the first day in ICU, d Average of mean daily blood glucose values for the 
first fourteen days, e All patients without CVS, f NS = Non-significant.  
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4.2. Analysis of Data 
 
As expected, patients that developed CVS displayed a higher clinical severity on 
admission (WFNSS 4.8 ± 1.01 vs. 3.56 ± 0.45, p < 0.05). A finding of cerebral oedema on 
initial radiologic examination was more frequently seen in patients who developed CVS 
(83.3% vs. 22.2%, p < 0.05).  
 
The mean inpatient blood glucose values (8.44 ± 1.98 mmol/L vs. 8.95 ± 2.54 mmol/L, 
p = 0.62) did not show a significant difference in mean in the development of CVS. However, 
contrary to expectations, a lower blood glucose value on admission (7.32 ± 1.58 mmol/L vs. 
9.28 ± 2.93 mmol/L, p < 0.05) and during the first 24 hours of ICU stay (7.26 ± 1.17 mmol/L 
vs. 9.29 ± 3.04 mmol/L, p < 0.05) was seen in patients with subsequent development of CVS 
(Figure 5.2.1.). Hyperglycaemia on admission (33.3% vs. 66.7%, p = 0.17) and during the 
first 24 hours of ICU stay (16.7% vs. 55.6%, p = 0.12) was less frequently seen in patients 
who developed CVS than patients who did not develop CVS.  
 
Figure 4.2.1 Comparison between mean admission, mean inpatient and mean 24-hour 
glucose value (mmol/L) and development of CVS
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People developing CVS had a shorter mean length of hospitalisation (12.83 ± 2.86 
days vs. 21.33 ± 14.49 days, p < 0.05) and we found that duration of ICU stay was negatively 
correlated to glucose averages of the first 24 hours of ICU stay (rs = -0.408, p < 0.05) (Figure 
4.2.2.) and almost significantly negatively correlated to mean inpatient glucose levels (rs = -
0.377, p = 0.07).  
 
Figure 4.2.2 Correlation between mean 24-hour glucose values and duration of ICU stay 
 
 
CVS (83.3% vs. 38.9%, p = 0.07) and signs of cerebral oedema on initial radiological 
examination (66.7% vs. 8.3% p < 0.05) were more frequently seen in patients that suffered 
from a fatal outcome. Differences in admission (9.18 ± 3.17 mmol/L vs. 8.4 ± 2.35 mmol/L, p 
= 0.5), mean 24-hour (8.87 ± 3.16 mmol/L vs. 8.7 ± 2.57 mmol/L, p = 0.89) and mean 
inpatient (9.44 ± 2.95 mmol/L vs. 8.21 ± 1.54 mmol/L, p = 0.21) blood glucose values did not 
show statistical significance to mortality. However, patients that suffered from a fatal 
outcome showed a negative correlation between duration of hospitalisation and glucose levels 
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on ICU admission (rs=-0.714, p < 0.05), mean 24-hour glucose levels (rs=-0.670, p < 0.05) 
and mean inpatient glucose levels (rs=-0.621, p < 0.05). 
 
4.2.1 Clinical predictors of CVS 
 
Cerebral oedema (RR, 8.29; 95% CI, 0.01 – 0.87; p = 0.01) and hydrocephalus (RR, 
4; 95% CI, 0.06 – 1.01; p = 0.05) were found to significantly increase the risk for CVS. 
Admission blood glucose (RR, 2.8; 95% CI, 0.8 – 1.59; p = 0.15), mean 24-hour blood 
glucose (RR, 4.23; 95% CI, 0.32 – 1.73; p = 0.1) and mean inpatient blood glucose (RR, 1.18; 
95% CI, 0.21 – 3.38; p = 0.6) were not found to be significant predictors of CVS (Table 
4.2.1.1.). The relative risk (RR) for the blood glucose values takes into account the adjusted 
RR for every 1 mmol/L decrease in blood glucose value below 7.8 mmol/L (since lower blood 
glucose values were associated with the development of CVS).  
 
Table 4.2.1.1 Multivariate analysis of factors associated with CVS after SAH 
Predictor Relative Risk 95% CI p Value a 
Cerebral Oedema 8.29 0.01 – 0.87 0.01 
Hydrocephalus 4 0.06 – 1.01 0.05 
Admission Glucose b 2.8 0.8 – 1.59 0.15 
Mean 24h Glucose b 4.23 0.32 – 1.73 0.1 
Mean Inpatient Glucose b 1.18 0.21 – 3.38 0.6 
CI = confidence interval, a Determined with chi-square test, b RR for every 1 mmol/L decrease 
in blood glucose value below 7.8 mmol/L 
 
 
 
 
 
 
 
 
 
 
 29 
5. DISCUSSION 
5.1. Discussion of Results 
 
 According to the results obtained from our study, we discovered that the development 
of CVS seems to be associated with lower blood glucose values on ICU admission and lower 
mean blood glucose values after 24 hours of ICU stay. Mean inpatient blood glucose levels 
did not show significant difference in groups to the development of CVS. Patients with lower 
blood glucose values on ICU admission also had a longer duration of ICU stay (possibly 
connected to the higher incidence of CVS development). A higher WFNSS and the presence 
of cerebral oedema on initial radiological examination also seem to be related to the 
development of CVS and patient mortality. This contrasts well with the findings of Ingawa, 
T., further endorsing the theory that severe SAH evident on CT-imaging appears to be a 
consistent risk factor for CVS [63]. 
 
An association between hypoglycaemia and neurologic deficit, in particular 
hemiparesis has been described in various studies and case reports dating all the way back to 
1928 [65 ,66]. A detailed literature review performed by Tetsuhiru et. al. in 2012 summarised 
articles from January 1950 to December 2010 that described cases of  newly discovered 
hemiplegia in hypoglycaemic patients [67]. Although the exact mechanism of hemiparesis in 
hypoglycaemic patients remains unclear, several studies included in the review associated a 
state of hypoglycaemia with the development of vasospasm.   
 
 Several more recent preceding studies have determined the importance of TGC of 
SAH patients in an ICU setting and have linked the development of CVS and worse patient 
outcome to episodes of hyperglycaemia throughout the entire ICU stay [8, 9, 13]. 
Hyperglycaemia on admission has also been investigated, however has thus far only been 
linked to changes in neurological grade [18] and increased incidence of morbidity and 
mortality [19]. The relationship to the development of CVS remains unclear. Two studies 
have focused on the effects of (mild) hypoglycaemia and patient outcome after SAH [7, 14], 
with emphasis being placed on the nadir (minimum) glucose value throughout ICU stay. After 
prospectively examining 172 patients with SAH, Naidech et. al. determined that a nadir 
glucose of ≤ 4.4 mmol/L is associated with cerebral infarction, vasospasm and worse 
functional outcome at 3 months after SAH [14]. The data in this study represented admission 
blood glucose values comparable to ours (8.93 vs. 8.79). Similar to our study, no differences 
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in mean inpatient blood glucose values were observed between patients who developed CVS 
and those that did not. Nevertheless, since only a single patient in our study presented with 
nadir glucose of ≤ 4.4 mmol/l throughout the entire ICU stay, it remains difficult to compare 
our results.  
 
Brain injury including aneurysmal SAH has already been linked to the initiation of 
metabolic derangements that indicate distress such as increased glutamate, glycerol, and 
lactate/pyruvate ratio [16, 17]. Two studies performed in 2006 and 2008 demonstrated that 
low levels of blood glucose following intensive insulin therapy (IIT) in the ICU were 
associated with increased prevalence of cerebral metabolic distress due to subsequently 
reduced cerebral glucose availability [16, 17]. In one study performed by Oddo et. al. [16], 
tight glycaemic control (blood glucose 4.4 – 6.7 mmol/L) was associated with a greater 
prevalence of low cerebral glucose and subsequent development of brain energy crisis 
compared to intermediate glycaemic control (6.8 – 10 mmol/L). The study determined that 
lower systemic glucose values independently predicted brain energy crisis, which in turn 
correlates with an increased mortality. Keeping the relationship between mild hypoglycaemia 
and the development of brain energy crisis in mind, one can postulate that the presence of a 
brain energy crisis due to lower blood glucose values on admission and after the first 24-hours 
of ICU stay may further contribute to the initial development of CVS and worse patient 
outcome. 
 
If lower blood glucose values on admission and within 24h of ICU stay are potentially 
hazardous after SAH, ICU protocols that define target glucose values may need to be refined 
for different ICU settings. Instead of immediate implementation of TGC with a target glucose 
range of 4.4 to 6.1 mmol/L as proposed by the Leuven Surgical Trials in 2001 [68], a delayed 
onset of aggressive insulin therapy could lead to improved clinical outcomes.  
 
5.2. Discussion of Limitations 
 
Certain limitations of this retrospective study were noted and deserve to be mentioned. 
First, it was not possible to accurately include all nutritional intake retrospectively, and this 
factor was not taken into account as a possible contribution to elevated / reduced blood 
glucose levels in the included patients. Nonetheless, all patients received standardised and 
appropriate nutritional support, therefore we do not believe that differences in nutritional 
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intake would have been significant enough to lead to changes in mean inpatient blood glucose 
levels.  
 
Second, the use of sedatives may have biased the clinical definition of CVS, especially 
in mechanically ventilated patients. It is well known that the use of sedatives may limit the 
detection of changes in neurologic status. However, using our methodology, we found 25% of 
SAH patients to develop CVS, which compares to similar findings from preceding studies [2, 
3].  
 
Third, we did not have access to data from invasive monitors such as brain oxygen 
tension or microdialysis parameters, so the mechanism of neuronal energy failure related to 
blood glucose values is speculative. Finally, in a great majority of the cases we relied on CTA 
for the initial diagnosis of CVS instead of the current DSA gold standard. This was mainly 
due to a lack of resources and requirement for rapid and early diagnosis. Nevertheless, CTA 
has proven to be a highly sensitive, specific and accurate diagnostic method with proof of 
good correlation to DSA [12].  
 
6. SUMMARY AND CONCLUSIONS 
In summary, we found that lower blood glucose values on ICU admission and after 
24h of ICU stay were associated with the development of CVS after SAH. Mean inpatient 
blood glucose values were not related to the development of CVS. While controlling blood 
glucose levels in an ICU setting remains an important factor in critical care, patients with 
SAH may benefit from protocols that aim for a wider target glucose range in order to avoid a 
state of hypoglycaemia, especially within the early stages of disease. The study cannot 
definitely establish causality, although it might spark refinement of standard glucose control 
protocols, especially in the early stages of ICU presentation.   
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IX. Zusammenfassung in deutscher Sprache 
 Der zerebrale Vasospasmus (ZVS) ist eine bekannte Ursache für Morbidität und 
Mortalität bei Patienten, die an einer Subarachnoidalblutung (SAB) gelitten haben. Seine 
Entstehung ist mit einer reduzierten zerebralen Perfusion und einer möglichen Entwicklung 
des neurologischen Defizits verbunden. Die Ätiologie von ZVS hat sich als multifaktoriell 
erwiesen und es wurden bereits mehrere Risikofaktoren mit seiner Entwicklung verbunden. 
Da ZVS mit Signalisierungsveränderungen im vaskulären Endothel bereits verknüpft wurde, 
haben wir die Serumglukose als potentiellen prognostischen Indikator und Risikofaktor, 
aufgrund ihrer Beziehung zur Endothel-Funktionsstörung gewählt. 
 
 Ziel dieser Studie war es, die Assoziation zwischen Serum-Glukosespiegel bei SAB-
Patienten und der Entwicklung von ZVS zu bewerten. Die retrospektive Studie beinhaltete 
Daten von Intensivpatienten der Pauls Stradiņš Universitätsklinik mit der primären Diagnose 
SAB. Wir verglichen die Aufnahme Serum-Glukosespiegel und die Glukosespiegel-
Mittelwerte für die ersten 5 Tage auf der Intensivstation bei Patienten mit und ohne 
anschließende Entwicklung von ZVS.  
 
 Insgesamt vierundzwanzig Patienten wurden in die Studie aufgenommen. ZVS wurde 
in 25% (n = 6) bestätigt. Es gab keinen signifikanten Unterschied in der Alters- und 
Geschlechterverteilung zwischen den Gruppen. Patienten mit ZVS hatten höhere WFNS-
Scores (4.80 und 3.56; p=0.008). Wir entdeckten niedrigere Aufnahme-Glukosewerte bei 
Patienten, die ZVS entwickelten (7.32 und 9.28 mmol/L; p=0.05). Die Glukose-Mittelwerte in 
den ersten 24 Stunden des Aufenthalts zeigten sich auch niedriger bei Patienten, die ZVS 
entwickelten (7.26 und 9.29 mmol/L; p=0.03). Es zeigten sich keine signifikanten 
Unterschiede im durchschnittlichen Glukosespiegel vom 2. bis zum 5. Tag des Aufenthalts. 
Mortalität wurde durch die Glukosespiegel nicht beeinflusst und die Glukose-Mittelwerte der 
ersten 24 Stunden korrelierten negativ mit der Dauer des Aufenthalts auf der Intensivstation 
(rs = -0.408, p<0,05). 
 
 Die Studie zeigt, dass Aufnahme- und Initiale 24 Stunden Glukosespiegel 
prognostische Indikatoren für die potenzielle Entwicklung von ZVS nach SAB sein könnten. 
Glukose-Mittelwerte am ersten Tag des Intensivaufenthalts waren mit der Entwicklung von 
ZVS signifikant verknüpft und könnten, nach weiterer Analyse, möglicherweise mit einer 
größeren Patientengruppe, eine bedeutende Geltung erzielen. 
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